Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers by Blanco, Ignacio et al.
RESEARCH ARTICLE
Assessing Associations between the AURKA-
HMMR-TPX2-TUBG1 Functional Module and
Breast Cancer Risk in BRCA1/2Mutation
Carriers
Ignacio Blanco1, Karoline Kuchenbaecker2, Daniel Cuadras3, XianshuWang4,
Daniel Barrowdale2, Gorka Ruiz de Garibay5, Pablo Librado6, Alejandro Sánchez-Gracia6,
Julio Rozas6, Núria Bonifaci5, Lesley McGuffog2, Vernon S. Pankratz7, Abul Islam8,
Francesca Mateo5, Antoni Berenguer3, Anna Petit9, Isabel Català9, Joan Brunet10,
Lidia Feliubadaló1, Eva Tornero1, Javier Benítez11, Ana Osorio11, Teresa Ramón y Cajal12,
Heli Nevanlinna13, Kristiina Aittomäki14, Banu K. Arun15, Amanda E. Toland16, Beth
Y. Karlan17, Christine Walsh17, Jenny Lester17, Mark H. Greene18, Phuong L. Mai18, Robert
L. Nussbaum19, Irene L. Andrulis20, Susan M. Domchek21, Katherine L. Nathanson21,
Timothy R. Rebbeck22, Rosa B. Barkardottir23, Anna Jakubowska24, Jan Lubinski24,
Katarzyna Durda24, Katarzyna Jaworska-Bieniek24, Kathleen Claes25, Tom Van Maerken25,
Orland Díez26, Thomas V. Hansen27, Lars Jønson27, Anne-Marie Gerdes28,
Bent Ejlertsen29, Miguel de la Hoya30, Trinidad Caldés30, Alison M. Dunning2, Clare Oliver2,
Elena Fineberg2, Margaret Cook2, Susan Peock2, EmmaMcCann31, Alex Murray32,
Chris Jacobs33, Gabriella Pichert33, Fiona Lalloo34, Carol Chu35, Huw Dorkins36,
Joan Paterson37, Kai-Ren Ong38, Manuel R. Teixeira39, Teixeira40, Frans B.
L. Hogervorst41, Annemarie H. van der Hout42, Caroline Seynaeve43, Rob B. van der
Luijt44, Marjolijn J. L. Ligtenberg45, Peter Devilee46,47, Juul T. Wijnen46,48, Matti
A. Rookus49, Hanne E. J. Meijers-Heijboer50, Marinus J. Blok51, Ans M. W. van den
Ouweland52, Cora M. Aalfs53, Gustavo C. Rodriguez54, Kelly-Anne A. Phillips55,
Marion Piedmonte56, Stacy R. Nerenstone57, Victoria L. Bae-Jump58, David M. O'Malley59,
Elena S. Ratner60, Rita K. Schmutzler61, BarbaraWappenschmidt61, Kerstin Rhiem61,
Christoph Engel62, Alfons Meindl63, Nina Ditsch64, Norbert Arnold65, Hansjoerg
J. Plendl66, Dieter Niederacher67, Christian Sutter68, ShanWang-Gohrke69,
Doris Steinemann70, Sabine Preisler-Adams71, Karin Kast72, Raymonda Varon-Mateeva73,
Andrea Gehrig74, Anders Bojesen75, Inge Sokilde Pedersen76, Lone Sunde77, Uffe
Birk Jensen77, Mads Thomassen78, Torben A. Kruse78, Lenka Foretova79,
Paolo Peterlongo80, Loris Bernard81, Bernard Peissel82, Giulietta Scuvera82,
Siranoush Manoukian82, Paolo Radice83, Laura Ottini84, Marco Montagna85,
Simona Agata85, Christine Maugard86, Jacques Simard87, Penny Soucy87,
Andreas Berger88, Anneliese Fink-Retter88, Christian F. Singer88, Christine Rappaport88,
Daphne Geschwantler-Kaulich88, Muy-Kheng Tea88, Georg Pfeiler88, BCFR89, Esther
M. John90, Alex Miron91, Susan L. Neuhausen92, Mary Beth Terry93, Wendy K. Chung94,
Mary B. Daly95, David E. Goldgar96, Ramunas Janavicius97, Cecilia M. Dorfling98, Elisabeth
J. van Rensburg98, Florentia Fostira99, Irene Konstantopoulou99, Judy Garber100, Andrew
K. Godwin101, Edith Olah102, Steven A. Narod103, Gad Rennert104, Shani Shimon Paluch105,
Yael Laitman106, Eitan Friedman106,107, SWE-BRCA108, Annelie Liljegren109,
Johanna Rantala110, Marie Stenmark-Askmalm111, Niklas Loman112, Evgeny
N. Imyanitov113, Ute Hamann114, kConFab Investigators115, Amanda B. Spurdle116,
Sue Healey116, Jeffrey N. Weitzel117, Josef Herzog117, David Margileth118,
Chiara Gorrini119, Manel Esteller120,121,122, Antonio Gómez120, Sergi Sayols120,
Enrique Vidal120, Holger Heyn120, GEMO123, Dominique Stoppa-Lyonnet124,125,126,
Melanie Léoné127, Laure Barjhoux128, Marion Fassy-Colcombet124, Antoine de Pauw124,
Christine Lasset129, Sandra Fert Ferrer130, Laurent Castera124, Pascaline Berthet131,
François Cornelis132, Yves-Jean Bignon133, Francesca Damiola128, Sylvie Mazoyer128,
PLOSONE | DOI:10.1371/journal.pone.0120020 April 1, 2015 1 / 18
OPEN ACCESS
Citation: Blanco I, Kuchenbaecker K, Cuadras D,
Wang X, Barrowdale D, de Garibay GR, et al. (2015)
Assessing Associations between the AURKA-HMMR-
TPX2-TUBG1 Functional Module and Breast Cancer
Risk in BRCA1/2 Mutation Carriers. PLoS ONE 10(4):
e0120020. doi:10.1371/journal.pone.0120020
Academic Editor: Hiromu Suzuki, Sapporo Medical
University, JAPAN
Received: June 25, 2014
Accepted: January 22, 2015
Published: April 1, 2015
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: BCFR—all. This work was supported by
grant UM1 CA164920 from the National Cancer
Institute. The content of this manuscript does not
necessarily reflect the views or policies of the
National Cancer Institute or any of the collaborating
centers in the Breast Cancer Family Registry
(BCFR), nor does mention of trade names,
commercial products, or organizations imply
endorsement by the United States Government or the
BCFR. BFBOCC: BFBOCC is supported by:
Olga M. Sinilnikova127,128†, Christopher A. Maxwell134, Joseph Vijai135, Mark Robson135,
Noah Kauff135, Marina J. Corines135, Danylko Villano135, Julie Cunningham4,7,
Adam Lee136, Noralane Lindor137, Conxi Lázaro1, Douglas F. Easton2, Kenneth Offit135,
Georgia Chenevix-Trench116, Fergus J. Couch4,7, Antonis C. Antoniou2*, Miguel
Angel Pujana5*
1 Hereditary Cancer Program, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical
Research (IDIBELL), L’Hospitalet del Llobregat, Catalonia, Spain, 2 Epidemiological Study of Familial Breast
Cancer (EMBRACE), Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom, 3 Statistics
Unit, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat, Catalonia, Spain, 4
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, United States of America, 5
Breast Cancer and Systems Biology Unit, Catalan Institute of Oncology (ICO), Bellvitge Institute for
Biomedical Research (IDIBELL), L’Hospitalet del Llobregat, Catalonia, Spain, 6 Department of Genetics and
Biodiversity Research Institute (IRBio), University of Barcelona, Barcelona, Catalonia, Spain, 7 Department
of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, 8 Department
of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh, 9 Department of
Pathology, University Hospital of Bellvitge, Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet
del Llobregat, Catalonia, Spain, 10 Hereditary Cancer Program, Catalan Institute of Oncology (ICO), Girona
Biomedical Research Institute (IDIBGI), Hospital Josep Trueta, Girona, Catalonia, Spain, 11 Human
Genetics Group, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases,
Madrid, Spain, 12 Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 13
Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital,
Helsinki, Finland, 14 Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland,
15 Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United
States of America, 16 Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular
Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University,
Columbus, Ohio, United States of America, 17 Women's Cancer Program at the Samuel Oschin
Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of
America, 18 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Maryland, Rockville, United States of America, 19 Department of Medicine and Genetics, University
of California San Francisco, San Francisco, California, United States of America, 20 Samuel Lunenfeld
Research Institute, Mount Sinai Hospital, and Departments of Molecular Genetics and Laboratory Medicine
and Pathobiology, University of Toronto, Toronto, Ontario, Canada, 21 Abramson Cancer Center and
Department of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania,
United States of America, 22 Abramson Cancer Center and Center for Clinical Epidemiology and
Biostatistics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania,
United States of America, 23 Department of Pathology, Landspitali University Hospital and BMC, Faculty of
Medicine, University of Iceland, Reykjavik, Iceland, 24 Department of Genetics and Pathology, Pomeranian
Medical University, Szczecin, Poland, 25 Center for Medical Genetics, Ghent University, Ghent, Belgium, 26
Oncogenetics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Research Institute (VHIR)
and Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain, 27 Center for Genomic Medicine,
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 28 Department of Clinical
Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 29 Department of
Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 30 Molecular Oncology
Laboratory, Hospital Clínico San Carlos, San Carlos Research Institute (IdISSC), Madrid, Spain, 31 All
Wales Medical Genetics Service, Glan Clwyd Hospital, Rhyl, United Kingdom, 32 All Wales Medical
Genetics Services, Singleton Hospital, Swansea, United Kingdom, 33 Clinical Genetics, Guy’s and
St. Thomas’ National Health Service (NHS) Foundation Trust, London, United Kingdom, 34 Genetic
Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals National
Health Service (NHS) Foundation Trust, Manchester, United Kingdom, 35 Yorkshire Regional Genetics
Service, Leeds, United Kingdom, 36 North West Thames Regional Genetics Service, Kennedy-Galton
Centre, Harrow, United Kingdom, 37 Department of Clinical Genetics, East Anglian Regional Genetics
Service, Addenbrookes Hospital, Cambridge, United Kingdom, 38 West Midlands Regional Genetics
Service, BirminghamWomen’s Hospital Healthcare National Health Service (NHS) Trust, Edgbaston,
Birmingham, United Kingdom, 39 Department of Genetics, Portuguese Oncology Institute, and Biomedical
Sciences Institute (ICBAS), Porto University, Porto, Portugal, 40 Hereditary Breast and Ovarian Cancer
Research Group Netherlands (HEBON), Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands,
41 Family Cancer Clinic, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands, 42 Department
of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands, 43
Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The
Netherlands, 44 Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The
Netherlands, 45 Department of Human Genetics and Department of Pathology, Radboud university medical
HMMR Functional Module and Breast Cancer Risk
PLOS ONE | DOI:10.1371/journal.pone.0120020 April 1, 2015 2 / 18
Lithuania (BFBOCC-LT): Research Council of
Lithuania grant LIG-07/2012 and Hereditary Cancer
Association (Paveldimo vėžio asociacija); Latvia
(BFBOCC-LV) is partly supported by LSC grant
10.0010.08 and in part by a grant from the ESF
Nr.2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016 and
Liepaja's municipal council. BMBSA: BRCA-gene
mutations and breast cancer in South African women
(BMBSA) was supported by grants from the Cancer
Association of South Africa (CANSA) to EJR.
BRICOH: SLN was partially supported by the Morris
and Horowitz Familes Endowed Professorship.
CBCS: This work was supported by the NEYE
Foundation. CNIO: This work was partially supported
by Spanish Association against Cancer (AECC08),
RTICC 06/0020/1060, FISPI08/1120, Mutua
Madrileña Foundation (FMMA) and SAF2010-20493.
COH-CCGCRN: City of Hope Clinical Cancer
Genetics Community Network and the Hereditary
Cancer Research Registry, supported in part by
Award Number RC4CA153828 (PI: JW) from the
National Cancer Institute and the Office of the
Director, National Institutes of Health. The content is
solely the responsibility of the authors and does not
necessarily represent the official views of the National
Institutes of Health. CONSIT TEAM: Funds from
Italian citizens who allocated the 5x1000 share of
their tax payment in support of the Fondazione
IRCCS Istituto Nazionale Tumori, according to Italian
laws (INT-Institutional strategic projects ‘5x1000’) to
SM. Italian Association for Cancer Research (AIRC)
to LO. CORE: The CIMBA data management and
data analysis were supported by Cancer Research—
United Kingdom grants C12292/A11174 and C1287/
A10118. SH is supported by an NHMRC Program
Grant to GCT. ACA is a Cancer Research -United
Kingdom Senior Cancer Research Fellow. GCT is an
NHMRC Senior Principal Research Fellow. DKFZ:
The DKFZ study was supported by the DKFZ.
DEMOKRITOS: This research has been co-financed
by the European Union (European Social Fund—
ESF) and Greek national funds through the
Operational Program "Education and Lifelong
Learning" of the National Strategic Reference
Framework (NSRF)—Research Funding Program of
the General Secretariat for Research & Technology:
ARISTEIA. Investing in knowledge society through
the European Social Fund. EMBRACE: EMBRACE is
supported by Cancer Research United Kingdom
Grants C1287/A10118 and C1287/A11990. DGE and
FL are supported by an National Institute of Health
Research (NIHR) grant to the Biomedical Research
Centre, Manchester. The Investigators at The Institute
of Cancer Research and The Royal Marsden NHS
Foundation Trust are supported by an NIHR grant to
the Biomedical Research Centre at The Institute of
Cancer Research and The Royal Marsden NHS
center, Nijmegen, The Netherlands, 46 Department of Human Genetics, Leiden University Medical Center,
Leiden, The Netherlands, 47 Department of Pathology, Leiden University Medical Center, Leiden, The
Netherlands, 48 Department of Clinical Genetics, Leiden University Medical Center, Leiden, The
Netherlands, 49 Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands,
50 Department of Clinical Genetics, Vrije Universiteit (VU) University Medical Centre, Amsterdam, The
Netherlands, 51 Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The
Netherlands, 52 Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The
Netherlands, 53 Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands,
54 Division of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Chicago,
Illinois, United States of America, 55 Division of Cancer Medicine, Peter MacCallum Cancer Centre, East
Melbourne, Victoria, Australia, 56 Gynecologic Oncology Group Statistical and Data Center, Roswell Park
Cancer Institute, Buffalo, New York, United States of America, 57 Central Connecticut Cancer Consortium,
Hartford Hospital/Helen and Harry Gray Cancer Center, Hartford, Connecticut, United States of America, 58
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina,
Chapel Hill, North Carolina, United States of America, 59 Division of Gynecologic Oncology, Ohio State
University, Columbus Cancer Council, Hilliard, Ohio, United States of America, 60 Division of Gynecologic
Oncology, Yale University School of Medicine, New Haven, Connecticut, United States of America, 61
Centre of Familial Breast and Ovarian Cancer and Centre for Integrated Oncology (CIO), University Hospital
of Cologne, Cologne, Germany, 62 Institute for Medical Informatics, Statistics and Epidemiology, University
of Leipzig, Leipzig, Germany, 63 Department of Gynecology and Obstetrics, Division of Tumor Genetics,
Klinikum Rechts der Isar, Technical University Munich, Munich, Germany, 64 Department of Gynecology
and Obstetrics, Ludwig-Maximilian University Munich, Munich, Germany, 65 Department of Gynecology and
Obstetrics, Christian-Albrechts-University of Kiel University Medical Center Schleswig-Holstein, Kiel,
Germany, 66 Institute of Human Genetics, Christian-Albrechts-University of Kiel University Medical Center
Schleswig-Holstein, Kiel, Germany, 67 Department of Gynecology and Obstetrics, University Hospital
Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, 68 Institute of Human Genetics,
Department of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany, 69 Department of
Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany, 70 Institute of Cell and Molecular
Pathology, Hannover Medical School, Hannover, Germany, 71 Institute of Human Genetics, University of
Münster, Münster, Germany, 72 Department of Gynecology and Obstetrics, University Hospital Carl Gustav
Carus, Technical University Dresden, Dresden, Germany, 73 Institute of Human Genetics, Campus Virchov
Klinikum, Charite Berlin, Berlin, Germany, 74 Centre of Familial Breast and Ovarian Cancer, Department of
Medical Genetics, Institute of Human Genetics, University Würzburg, Würzburg, Germany, 75 Department of
Clinical Genetics, Vejle Hospital, Vejle, Denmark, 76 Section of Molecular Diagnostics, Department of
Biochemistry, Aalborg University Hospital, Aalborg, Denmark, 77 Department of Clinical Genetics, Aarhus
University Hospital, Aarhus, Denmark, 78 Department of Clinical Genetics, Odense University Hospital,
Odense, Denmark, 79 Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer
Institute, Brno, Czech Republic, 80 Fondazione Istituto di Oncologia Molecolare (IFOM), Fondazione Italiana
per la Ricerca sul Cancro (FIRC), Milan, Italy, 81 Department of Experimental Oncology, Istituto Europeo di
Oncologia (IEO), Cogentech Cancer Genetic Test Laboratory, Milan, Italy, 82 Unit of Medical Genetics,
Department of Preventive and Predictive Medicine, Istituto di Ricovero e Cura a Carattere Scientifico
(IRCCS), Fondazione Istituto Nazionale Tumori (INT), Milan, Italy, 83 Unit of Molecular Bases of Genetic
Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Istituto di Ricovero e Cura a
Carattere Scientifico (IRCCS), Fondazione Istituto Nazionale Tumori (INT), Milan, Italy, 84 Department of
Molecular Medicine, "Sapienza" University, Rome, Italy, 85 Immunology and Molecular Oncology Unit,
Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy, 86
Laboratoire de Diagnostic Génétique et Service d'Onco-Hématologie, Hopitaux Universitaire de Strasbourg,
Centre Hospitalier Régional Universitaire (CHRU) Nouvel Hôpital Civil, Strasbourg, France, 87 Cancer
Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University,
Quebec City, Canada, 88 Department of Gynecology and Obstetrics, and Comprehensive Cancer Center,
Medical University of Vienna, Vienna, Austria, 89 Breast Cancer Family Registry (BCFR), Cancer Prevention
Institute of California, Fremont, California, United States of America, 90 Department of Epidemiology, Cancer
Prevention Institute of California, Fremont, California, United States of America, 91 Department of Cancer
Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 92 Department of
Population Sciences, Beckman Research Institute of City of Hope, Duarte, California, United States of
America, 93 Department of Epidemiology, Columbia University, New York, New York, United States of
America, 94 Departments of Pediatrics and Medicine, Columbia University Medical Center, New York, New
York, United States of America, 95 Department of Clinical Genetics, Fox Chase Cancer Center,
Philadelphia, Pennsylvania, United States of America, 96 Department of Dermatology, University of Utah
School of Medicine, Salt Lake City, Utah, United States of America, 97 Vilnius University Hospital Santariskiu
Clinics, Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and
Regenerative Medicine, State Research Centre Institute for Innovative medicine, Vilnius, Lithuania, 98
Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, Arcadia, South Africa, 99
HMMR Functional Module and Breast Cancer Risk
PLOS ONE | DOI:10.1371/journal.pone.0120020 April 1, 2015 3 / 18
Foundation Trust. RE and EB are supported by
Cancer Research United Kingdom Grant C5047/
A8385. FCCC: The authors acknowledge support
from The University of Kansas Cancer Center (P30
CA168524) and the Kansas Bioscience Authority
Eminent Scholar Program. AKG was funded by
5U01CA113916, R01CA140323, and by the
Chancellors Distinguished Chair in Biomedical
Sciences Professorship. GC-HBOC: The German
Consortium of Hereditary Breast and Ovarian Cancer
(GC-HBOC) is supported by the German Cancer Aid
(grant no 109076, RKS) and by the Center for
Molecular Medicine Cologne (CMMC). GEMO: The
study was supported by the Ligue National Contre le
Cancer; the Association “Le cancer du sein, parlons-
en!” Award; and the Canadian Institutes of Health
Research for the "CIHR Team in Familial Risks of
Breast Cancer" program. G-FAST: TVM is a
postdoctoral researcher funded by the Fund for
Scientific Research Flanders (FWO). GOG: This
study was supported by National Cancer Institute
grants to the Gynecologic Oncology Group (GOG)
Administrative Office and Tissue Bank (CA 27469),
the GOG Statistical and Data Center (CA 37517), and
GOG's Cancer Prevention and Control Committee
(CA 101165). MHG, PLM and Dr. Savage were
supported by funding from the Intramural Research
Program, NCI. HCSC: Was supported by a grant
RD12/00369/0006 and 12/00539 from ISCIII (Spain),
partially supported by European Regional
Development FEDER funds. HEBCS: The HEBCS
was financially supported by the Helsinki University
Central Hospital Research Fund, Academy of Finland
(132473), the Finnish Cancer Society and the Sigrid
Juselius Foundation. HEBON: The HEBON study is
supported by the Dutch Cancer Society grants
NKI1998-1854, NKI2004-3088, NKI2007-3756, the
Netherlands Organization of Scientific Research
grant NWO 91109024, the Pink Ribbon grant 110005
and the BBMRI grant NWO 184.021.007/CP46.
HUNBOCS: Hungarian Breast and Ovarian Cancer
Study was supported by Hungarian Research Grant
KTIA-OTKA CK-80745 and the Norwegian EEA
Financial Mechanism HU0115/NA/2008-3/ÖP-9. ICO:
The ICO-IDIBELL study was supported by grants
from the Spanish Ministry of Health ISCIII FIS (PI10/
01422, PI12/01528, and PI13/00285) and RTICC
(RD12/0036/0008); the Ramón Areces (XV), Eugenio
Rodríguez Pascual (2012), and Roses Contra el
Cancer (2012) Foundations; the Spanish Association
Against Cancer (AECC 2010); and the AGAUR
Generalitat de Catalunya (2009-SGR290 and 2009-
SGR293). IHCC: The IHCC was supported by Grant
PBZ_KBN_122/P05/2004; Katarzyna Jaworska is a
fellow of International PhD program, Postgraduate
School of Molecular Medicine, Warsaw Medical
University, supported by the Polish Foundation of
Molecular Diagnostics Laboratory, Institute of Radioisotopes and Radiodiagnostic Products (IRRP), National
Centre for Scientific Research Demokritos, Athens, Greece, 100 Center for Cancer Genetics and Prevention,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America,
101 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City,
Kansas, United States of America, 102 Department of Molecular Genetics, National Institute of Oncology,
Budapest, Hungary, 103 Women's College Research Institute, University of Toronto, Toronto, Canada, 104
Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology,
Carmel Medical Center and B Rappaport Faculty of Medicine, Haifa, Israel, 105 The Institute of Oncology,
Chaim Sheba Medical Center, Ramat Gan, Israel, 106 The Susanne Levy Gertner Oncogenetics Unit,
Institute of Human Genetics, Chaim Sheba Medical Center, Ramat Gan, Israel, 107 Sackler Faculty of
Medicine, Tel Aviv University, Ramat Aviv, Israel, 108 Swedish BRCA1 and BRCA2 Study (SWE-BRCA),
Stockholm, Sweden, 109 Department of Oncology, Karolinska University Hospital, Stockholm, Sweden, 110
Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden, 111 Division of Clinical
Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, 112
Department of Oncology, Lund University Hospital, Lund, Sweden, 113 N.N. Petrov Institute of Oncology,
St.-Petersburg, Russia, 114 Molecular Genetics of Breast Cancer, German Cancer Research Center
(DKFZ), Heidelberg, Germany, 115 Kathleen CuninghamConsortium for Research into Familial Breast
Cancer (kConFab), Peter MacCallum Cancer Center, Melbourne, Australia, 116 Queensland Institute of
Medical Research (QIMR) Berghofer Medical Research Institute, Brisbane, Australia, 117 Clinical Cancer
Genetics, City of Hope, Duarte, California, United States of America, 118 St. Joseph Hospital of Orange,
Care of City of Hope Clinical Cancer Genetics Community Research Network, Duarte, California, United
States of America, 119 The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute,
University Health Network, Toronto, Canada, 120 Cancer Epigenetics and Biology Program (PEBC),
IDIBELL, L’Hospitalet del Llobregat, Catalonia, Spain, 121 Department of Physiological Sciences II, School
of Medicine, University of Barcelona, L’Hospitalet del Llobregat, Catalonia, Spain, 122 Catalan Institution for
Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain, 123 Groupe Genetique et Cancer
(GEMO), National Cancer Genetics Network, French Federation of Comprehensive Cancer Centers
(UNICANCER), Paris, France, 124 Department of Tumour Biology, Institut Curie, Paris, France, 125 Institut
National de la Santé et de la Recherche Médicale (INSERM) U830, Institut Curie, Paris, France, 126
Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 127 Unité Mixte de Génétique
Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon–Centre Léon Bérard, Lyon, France, 128
Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Centre National de la Recherche
Scientifique (CNRS) UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon,
France, 129 Université Lyon 1, Centre National de la Recherche Scientifique (CNRS) UMR5558, and Unité
de Prévention et d’Epidémiologie Génétique, Centre Léon Bérard, Lyon, France, 130 Laboratoire de
Génétique Chromosomique, Hôtel Dieu Centre Hospitalier, Chambéry, France, 131 Centre François
Baclesse, Caen, France, 132 Genetic Unit, Avicenne Hospital, Assitance Publique-Hôpitaux de Paris, Paris,
Sud-Francilien Hospital, Evry-Corbeil, and University Hospital, Clermont-Ferrand, France, 133 Département
d'Oncogénétique, Centre Jean Perrin, Université de Clermont-Ferrand, Clermont-Ferrand, France, 134
Department of Pediatrics, Child and Family Research Institute, University of British Columbia, Vancouver,
Canada, 135 Clinical Genetics Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York,
New York, United States of America, 136 Department of Oncology, Mayo Clinic, Rochester, Minnesota,
United States of America, 137 Center for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, United
States of America
†Deceased.
* aca20@medschl.cam.ac.uk (ACA); mapujana@iconcologia.net (MAP)
Abstract
While interplay between BRCA1 and AURKA-RHAMM-TPX2-TUBG1 regulates mammary
epithelial polarization, common genetic variation in HMMR (gene product RHAMM) may be
associated with risk of breast cancer in BRCA1mutation carriers. Following on these obser-
vations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional
module and risk of breast cancer in BRCA1 or BRCA2mutation carriers. Forty-one single
nucleotide polymorphisms (SNPs) were genotyped in 15,252 BRCA1 and 8,211 BRCA2
mutation carriers and subsequently analyzed using a retrospective likelihood approach.
The association of HMMR rs299290 with breast cancer risk in BRCA1 mutation carriers
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was confirmed: per-allele hazard ratio (HR) = 1.10, 95% confidence interval (CI) 1.04 –
1.15, p = 1.9 x 10−4 (false discovery rate (FDR)-adjusted p = 0.043). Variation in CSTF1, lo-
cated next to AURKA, was also found to be associated with breast cancer risk in BRCA2
mutation carriers: rs2426618 per-allele HR = 1.10, 95% CI 1.03 – 1.16, p = 0.005 (FDR-ad-
justed p = 0.045). Assessment of pairwise interactions provided suggestions (FDR-adjusted
pinteraction values> 0.05) for deviations from the multiplicative model for rs299290 and
CSTF1 rs6064391, and rs299290 and TUBG1 rs11649877 in both BRCA1 and BRCA2mu-
tation carriers. Following these suggestions, the expression of HMMR and AURKA or
TUBG1 in sporadic breast tumors was found to potentially interact, influencing patients’ sur-
vival. Together, the results of this study support the hypothesis of a causative link between
altered function of AURKA-HMMR-TPX2-TUBG1 and breast carcinogenesis in BRCA1/2
mutation carriers.
Introduction
An integrative genomics study generated a breast cancer network model that predicted novel
genetic and molecular relationships for breast cancer tumor suppressors [1]. Among the pre-
dictions, the product of the hyaluronan-mediated motility receptor (HMMR) gene, RHAMM,
was found to be biochemically and functionally linked to the breast cancer gene, early onset 1
gene product (BRCA1) [1]. Analysis of common genetic variation in HMMR suggested an as-
sociation with breast cancer risk in Ashkenazi Jewish women, with a greater increased risk in
younger individuals [1]. However, this association was not observed either in a European case-
control study [2] or in a genome-wide association study in postmenopausal women of Europe-
an ancestry [3].
Following the initial functional evidence, a molecular mechanism involving RHAMM and
BRCA1 was found to regulate mammary epithelial apicobasal polarization and, possibly, differ-
entiation [4]. The results from this study indicated that RHAMM and BRCA1 play a central
role in the cytoskeletal reorganization necessary for epithelial polarization. This functional in-
terplay included interactions with the product of the proto-oncogene aurora kinase A
(AURKA) and its major regulator, targeting protein for Xklp2 (TPX2), in addition to g-tubulin
(TUBG1) [4]. In this scenario, cell proliferation is endorsed by activated AURKA while polari-
zation and differentiation are mediated by activation of BRCA1 and degradation of RHAMM.
Intriguingly, the same HMMR variation as originally detected in the Ashkenazi Jewish popula-
tion was suggested to be associated with breast cancer risk in BRCA1, but not in BRCA2muta-
tion carriers [4]. This observation was endorsed by complementary analyses in breast cancer
tissue; specifically, loss of cell polarity was revealed in in situ breast tissue lesions of BRCA1
mutation carriers and, accordingly, increased staining of phospho-T703-RHAMM (target of
AURKA) was preferentially detected in estrogen receptor α (ERα)-negative and BRCA1-mutat-
ed tumors [4].
While theHMMR association study in BRCA1/2mutation carriers drew on a partial dataset
from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), the depicted mecha-
nistic model highlighted additional gene candidates for breast cancer risk; i.e., AURKA, TPX2,
and TUBG1 [4]. In a previous CIMBA study, no evidence of association was found between
functional variation in AURKA and breast cancer risk among BRCA1/2mutation carriers [5].
However, these results were based on a more limited CIMBA dataset (4,935 BRCA1 and 2,241
BRCA2mutation carriers) and did not comprehensively assess variation in the AURKA
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genomic region. Furthermore, variation in TUBG1 was found to be associated with breast can-
cer risk in a hospital-based case-control study [6], but has not been assessed in BRCA1/2
mutation carriers.
In addition to multiplicative allele effects, systematic analyses in model organisms have
shown that a given phenotype may be substantially determined by genetic interactions (GxG);
that is, “epistasis” in statistical terms, defined as deviation from additivity for a quantitative
phenotype arising from the effect of genetic variants or mutations in another locus [7]. Impor-
tantly, GxG significantly overlap with other types of gene and/or protein relationships [8–10].
Therefore, the functional interplay between the aforementioned genes/proteins in a key mam-
mary epithelial cell process could support the existence of genetic interactions that influence
cancer risk.
In the present study, given previous evidence of 1) the functional interplay between BRCA1
and AURKA-RHAMM-TPX2-TUBG1 in mammary epithelial polarization [4], and 2) the po-
tential modification of breast cancer risk in BRCA1mutation carriers by common genetic vari-
ation inHMMR [4], we further assessed the association between variants in
AURKA-HMMR-TPX2-TUBG1 and breast cancer risk in BRCA1 and BRCA2mutation carri-
ers. Genotyped variants from the custom Illumina iSelect array of the Collaborative Oncologi-
cal Gene-environment Study (iCOGS) were analyzed in a large series of BRCA1/2mutation
carriers [11,12].
Materials and Methods
Study Subjects and Ethics Statement
BRCA1/2mutation carriers were recruited under the CIMBA initiative following approval of
the corresponding protocol by the institutional review board or ethics committee at each par-
ticipating center, and written informed consent was obtained from the patients when required
[11,12]. Sixty CIMBA study centers recruited 15,252 BRCA1 and 8,211 BRCA2mutation carri-
ers that passed quality control assessment in this study. Most of these individuals were re-
cruited through cancer genetics clinics and enrolled into national or regional studies. The
remaining carriers were identified by population-based sampling or community recruitment.
Eligibility in CIMBA was restricted to female carriers of pathogenic BRCA1 and BRCA2muta-
tions who were 18 years old at recruitment. Information collected included year of birth,
mutation description, self-reported ethnicity, age at last follow-up, ages at breast or ovarian
cancer diagnosis, and age at bilateral prophylactic mastectomy or oophorectomy. Information
regarding tumor characteristics, including ERα status, was collected for 3,458 BRCA1 and
1,924 BRCA2mutation carriers. Related individuals were identified by a unique family
identifier.
iCOGS Design
The iCOGS array, genotyping and quality controls for the CIMBA BRCA1/2mutation carrier
samples have been described recently [11,12]. The final array design included 211,155 manu-
factured SNPs that were selected on the basis of primary evidence from genome-wide associa-
tion studies (GWASs) of breast, ovarian and prostate cancer, for fine mapping of known
cancer susceptibility loci, and included functional candidate variants of interest [11–15] (also
see http://www.nature.com/icogs/primer/cogs-project-and-design-of-the-icogs-array/ and
http://ccge.medschl.cam.ac.uk/research/consortia/icogs/). Details of the iCOGS array design
have been described elsewhere [11–15]. The genotype data used in this study are available
upon request from the CIMBA Data Access Coordinating Committee (contact A.C.A.).
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Association Study
Based on previous GWAS results for BRCA1 [16] and BRCA2 [17] mutation carriers, and on
the selection of gene candidates, the iCOGS array included SNPs in the AURKA (n = 15),
HMMR (n = 14), TPX2 (n = 3) and TUBG1 (n = 4) loci (defined as ± 20 kilobases (kb) from the
genomic structure of each gene), and these were analyzed in the present study (S1 Table). In
addition, we analyzed five SNPs proximal to theHMMR locus that provided some suggestion
of association with breast cancer risk in Ashkenazi Jewish women [1] (S1 Table). In total, these
SNPs represented 32 partially independent variants (pairwise r2< 0.85). To account for multi-
ple testing, we used a FDR approach for the 41 genotyped SNPs that were evaluated for their
associations with breast cancer risk in BRCA1 and BRCA2mutation carriers; significant results
are reported for FDR< 5%. The main analyses focused on evaluating associations between
each genotype and breast cancer or ovarian cancer risk separately, in a survival analysis frame-
work. In the breast cancer analysis, the phenotype of each individual was defined by age at
breast cancer diagnosis or age at last follow-up. Individuals were followed until the age of the
first breast or ovarian cancer diagnosis or bilateral prophylactic mastectomy, whichever oc-
curred first, or until age at last observation. Mutation carriers censored at ovarian cancer diag-
nosis were considered to be unaffected. For the ovarian cancer analysis, the primary endpoint
was the age at ovarian cancer diagnosis, and mutation carriers were followed until the age of
ovarian cancer diagnosis or risk-reducing salpingo-oophorectomy, or until age at last observa-
tion. In order to maximize the number of ovarian cancer cases, breast cancer was not consid-
ered to be a censoring event in this analysis, and mutation carriers who developed ovarian
cancer after breast cancer diagnosis were considered affected in the ovarian cancer analysis. To
adjust for the non-random sampling of mutation carriers with respect to their disease status,
data were analyzed by modeling the retrospective likelihood of the observed genotypes condi-
tional on the disease phenotypes [18]. The associations were assessed using the 1-degree of
freedom score test statistic based on this retrospective likelihood. To allow for the non-inde-
pendence among related individuals, the correlation between the genotypes was taken into ac-
count using a kinship-adjusted version of the score test statistic [16]. The p values presented
were based on the adjusted score test. To estimate the HRs, the effect of each SNP was modeled
as either a per-allele or genotype on the log-scale by maximizing the retrospective likelihood.
The evidence of heterogeneity in the associations between countries/study-centers was also
evaluated. Associations with breast and ovarian cancer risks were assessed simultaneously
within a competing risk analysis framework [11,18]. The significant FDR-adjusted associations
(for rs299290 inHMMR and for rs2426618 in AURKA/CSTF1) were subsequently explored
using imputed genotypes based on data from the 1,000 Genomes project (March 2012 version
[19]). The IMPUTE2 software [20] was used for imputation of non-genotyped SNPs. Associa-
tions of each marker with cancer risk were assessed using a similar score test to that used for
the genotyped SNPs, but based on the posterior genotype probabilities at each imputed marker
for each individual. In all analyses, only those SNPs with an imputation information/accuracy
of r2> 0.30 and a minor allele frequency (MAF)> 0.3 were considered. The haplotypes and
their posterior probabilities were estimated using the expectation-maximization algorithm
[21]. Only the four HMMR haplotypes with the highest probabilities were considered; the rest
were grouped into a single rare haplotype. Each carrier was assigned the most likely haplotypes
and the association between haplotypes and age at breast cancer diagnosis was evaluated using
a standard Cox proportional hazards model. All possible pairwise gene interactions including
rs299290 or rs2426618 were evaluated using a standard Cox proportional hazards model that
considered the main effects and the interaction term.
HMMR Functional Module and Breast Cancer Risk
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Expression Analysis
The association between gene expression and survival after breast cancer diagnosis was as-
sessed using the NKI-295 dataset of sporadic primary breast tumors [22,23] and a standard
Cox proportional hazards model. All possible pairwise gene interactions including HMMR or
AURKAmicroarray probes (2 and 1 probes, respectively) were evaluated using this model. The
quantitative analysis of HMMR expression isoforms was carried out using mRNA extracted
from lymphoblastoid cell lines of nine rs299290-TT and six rs299290-CC BRCA2mutation
carriers, and the following TaqMan (Applied Biosystems) probes in real-time PCR assays:
hs01063269 for totalHMMR expression; hs0106328 for the inclusion of exon 4; and
hs00234864 for the inclusion of exon 11.
Genome Analyses
Data for formaldehyde-assisted isolation of regulatory elements (FAIREs) that marked tran-
scriptionally active regions in normal human mammary epithelial cells (HMECs) were down-
loaded from the Gene Expression Omnibus (GEO) reference GSE46074 [24]. Sequence reads
were trimmed for the adaptor, masked for low-complexity and low-quality sequences/reads
and subsequently aligned to the genome version hg19 using TopHat [25] with default parame-
ters. Peaks were called using HOMER [26], applying a triangle-based distribution, a median
length of 150 base pairs, and an α value of 0.01 (99.0% CI). Replicates were analyzed individu-
ally and uniquely merged using BEDTools [27]. Chromatin immunoprecipitation data of ERα
were downloaded from the GEO reference GSE32222 and analyzed with MACS (version 2.0.9;
macs2diff function) [28]. Significance was defined as a false discovery rate< 1%, using default
values for all other parameters. Differentially bound genomic regions were assigned to the clos-
est ENSEMBL (version 62) annotated gene using the R-Bioconductor package ChIPpeakAnno
[29]. Histone modification and chromatin segmentation data in HMECs were obtained from
the UCSC Genome Browser (hg19) and correspond to the GEO references GSE29611 and
GSE38163, respectively, deposited by the ENCODE project [30].
Evolutionary analysis of BRCA1 and RHAMM
The full-length nucleotide and protein sequences from 20 (for BRCA1/BRCA1) and 26 (for
HMMR/RHAMM) mammalian species, which included human and naked mole rat, were
downloaded from the OrthoMaM 2.0 database [31] (S2 Table). For evolutionary analysis, a
multiple sequence alignment (MSA) of the corresponding amino acid sequences was generated
using the algorithm implemented in PRANK v.140110 [32]. To prevent the inclusion of incor-
rectly aligned positions, all MSA positions with low statistical support (posterior
probabilities< 0.99) in the PRANK alignment were excluded. Next, the high-quality protein
MSAs were used as guide in the alignment of the corresponding coding sequences (CDS
MSAs). The level of functional constraints acting on the coding regions of both genes was ana-
lyzed using the maximum likelihood method implemented in the codeml program of PAML
v.4 [33]; this approach allows to estimate the non-synonymous (dN) to synonymous (dS) ratio
(ω) in a particular coding region by using a codon-based evolutionary model under a phyloge-
netic framework, allowing comparison of their fit to the data by the likelihood ratio test (LRT).
In particular, the goodness-of-fit of two nested evolutionary models was compared: the M7
model, which assumes a β distribution of ω across sites between 0 and 1 (0 ω 1); and the
M8 model, which adds to M7 an extra category of positively selected sites (ω> 1). To reduce
the probability of false positive results from the M7-M8 comparison, we also estimated the like-
lihood of the data under the model M8a [34], in which ω was set to 1. The posterior probabili-
ties for each site of belonging to the positively selected class were computed using the Bayes
HMMR Functional Module and Breast Cancer Risk
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empirical Bayes approach in codeml [35]. In all models, the topology of the mammalian phylo-
genetic tree assumed in OrthoMaM database was used (S2 Table).
Results
HMMR rs299290 Association
The product of the HMMR gene, RHAMM, interacts with BRCA1 in the control of mammary
epithelial polarization and this function may be at the basis of a modification of breast cancer
risk in BRCA1mutation carriers [4]. In this iCOGS BRCA1/2 study, 14 SNPs (11 with pairwise
r2< 0.85) at theHMMR locus were genotyped in 15,252 BRCA1 and 8,211 BRCA2mutation
carriers from 60 participating centers. Among these variants, the strongest evidence of associa-
tion with breast cancer risk in BRCA1mutation carriers was observed for the originally re-
ported SNP rs299290 [4] (MAF = 0.25): BRCA1 per-allele HR = 1.10, 95% CI 1.04–1.15, p = 1.9
x 10−4 (FDR-adjusted p = 0.043, accounting for 41 genotyped SNPs used in the association
analyses in BRCA1 and BRCA2mutation carriers). In contrast, no evidence of association was
obtained between HMMR variation and breast cancer risk in BRCA2mutation carriers; specifi-
cally, rs299290 per-allele HR = 0.98, 95% CI 0.92–1.05, p = 0.57. The effect among BRCA1mu-
tation carriers was consistent across most participating countries (Fig. 1A) and no
heterogeneity was detected (pheterogeneity 0.30). Importantly, the BRCA1 association remained
after excluding the centers participating in the original study [4]: n = 5,039, rs299290 per-allele
HR = 1.13, 95% CI 1.04–1.22, p = 0.005.
Although the original Ashkenazi Jewish population study suggested associations involving
SNPs proximal toHMMR (*450 kb proximal) [1], no evidence of association in BRCA1/2mu-
tation carriers was obtained for five correlated variants in this region (S1 Table). With respect
to rs299290 and ovarian cancer risk, no evidence of association was found under the single dis-
ease risk model or the competing risks model (p> 0.65; only breast cancer risk in BRCA1mu-
tation carriers was significant in this model: p = 2.5 x 10−4). Together, these results corroborate
the association between variation at theHMMR locus and breast cancer risk in BRCA1muta-
tion carriers.
Mapping the HMMR locus association
Allelic imputation within*60 kb centered on HMMR (fully including the proximal genes
CCNG1 and NUDCD2) did not detect substantially stronger associations than those identified
for rs299290: a variant located inHMMR intron 7 (rs61292050; Fig. 1B) was found to be simi-
larly associated (p = 2.7 x 10−4), but this was correlated with rs299290 (r2 = 0.95). Haplotype
analyses were then carried out to demarcate theHMMR genomic region potentially harboring
a causative variant or mutation. Using the 14 SNPs genotyped in iCOGS, two haplotypes, both
characterized by the minor allele of rs299290, were found to be associated with breast cancer
risk in BRCA1mutation carriers (S3 Table). Based on these haplotypes, the minimal region
harboring a mutation could be delimited to*28 kb between rs299284 and rs10038157
(S3 Table).
Analysis of the potential causative variant
The rs299290 variant represents a missense amino-acid change in HMMR exon 11 that is pre-
dicted to be benign/neutral/tolerated by several algorithms: Valine 369 to Alanine in accession
number NP_001136028.1; MutationAssessor score = 0; Polyphen score = 0.005; and SIFT
score = 0.73. Subsequent examination of the splicing of exon 11 and of exon 4, the latter of
which is known to be differentially spliced in different conditions and cell types [36], did not
HMMR Functional Module and Breast Cancer Risk
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reveal alterations or differences between mRNA samples with different rs299290 genotypes
(S1 Fig.). Nonetheless, rs299290 is located*14 kb from theHMMR promoter region that is
active in mammary epithelial cells, as detected by the analysis of data from genome occupancy
profiling [24] (Fig. 1B). In addition, analysis of data for ERα binding plasticity [37] revealed
significant binding of this factor at the HMMR promoter in poor-prognosis breast tumors
(Fig. 1B).
Causal alleles for different common diseases have shown evidence of positive selection [38].
Notably, a recent report suggested the action of positive selection on the evolution of BRCA1
and RHAMM orthologs in the naked mole rat, which is an exceptionally cancer-resistant spe-
cies [39]. Following on from this suggestion, we identified footprints of positive selection in the
evolution of some amino acids of both proteins. In both cases, model M8 (selection model) bet-
ter fits the protein alignment data than model M7 (null model): p values = 6.69 x 10−14 and
1.55 x 10−5, for BRCA1 and RHAMM, respectively. Moreover, the likelihood of the data is sig-
nificantly higher under model M8 than under the nested model M8a: p values = 6.22 x 10−10
Fig 1. TheHMMR locus and breast cancer risk in BRCA1mutation carriers. (A) Forest plots showing
rs299290 HRs and 95%CIs (retrospective likelihood trend estimation) for participating countries (relatively
small sample sets are not shown) ordered by sample size. Left and right panels show results for BRCA1 and
BRCA2mutation carriers, respectively. The sizes of the rectangles are proportional to the corresponding
country/study precision. (B) The rs299290-containing region, including the genes, variation and regulatory
evidence mentioned in HMECs. Exons are marked by black-filled rectangles and the direction of transcription
is marked by arrows in the genomic structure. The chromosome 5 positions (base pairs (bp)) and linkage
disequilibrium structure from Caucasian HapMap individuals are also shown.
doi:10.1371/journal.pone.0120020.g001
HMMR Functional Module and Breast Cancer Risk
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and 0.014 for BRCA1 and RHAMM, respectively, confirming the presence of positively select-
ed sites in these alignments. However, Valine 369 RHAMMwas not identified in these analy-
ses; the predicted amino acid sites under selection were only linked to rare variants
(MAFs< 0.01) (S4 Table). Nonetheless, as suggested in the analysis of the naked mole rat se-
quence, Valine 369 is within a region with a potential excess of selected positions (Fig. 2A).
Analysis of BRCA1 also showed multiple potential selection sites (Fig. 2B), but the specific re-
gion or domain mediating the interaction with RHAMM remains unknown [1,4,40].
Evaluation of HMMR association by ERα tumor status and BRCA1
mutation class
The original study suggested an association between the rs299290 risk allele and ERα-negative
breast cancer for BRCA1mutation carriers [4]. In the present study, no difference was found in
the rs299290 effect between ERα-negative and ERα-positive cases: ERα-negative, per-allele
HR = 1.09, 95% CI 1.03–1.15, p = 2.3 x 10−3; ERα-positive, per-allele HR = 1.09, 95% CI 0.98–
1.21, p = 0.13; pdifference = 0.96. Interestingly, there was a suggestion of an rs299290 association
with ERα-negative breast cancer for BRCA2mutation carriers, but in the opposite direction to
that observed for BRCA1mutation carriers: ERα-negative BRCA2mutation carriers n = 434,
per-allele HR = 0.83, 95% CI 0.70–0.97, p = 0.022. In addition, there was no evidence of an
rs299290 association with ERα-positive breast cancer in BRCA2mutation carriers (n = 1,490,
p = 0.40, ERα-negative effect pdifference = 0.019).
Regarding BRCA1mutation classes, the original study [4] suggested a rs299290 association
in carriers of mutations expected to result in a reduced transcript or protein level due to non-
sense-mediated RNA decay (Class 1), but not in carriers of mutations likely to generate stable
proteins with a potential residual or dominant-negative function (Class 2). The current study
indicated a similar association, although the estimations were not significantly different: Class
1, rs299290 per-allele HR = 1.11, 95% CI 1.05–1.18, p = 4.6 x 10−4; Class 2, rs299290 per-allele
HR = 1.03, 95% CI 0.94–1.14, p = 0.51. Regarding Ashkenazi Jewish BRCA1mutation carriers
(n = 1,231), there were no significant associations in this population or with founder mutations
(185delAG HR = 0.94, p = 0.17; and 5382insC HR = 0.85, p = 0.10). Larger sample series may
Fig 2. Candidate amino acid sites under positive selection in RHAMM and BRCA1. (A) Plot showing the
position of potentially selected sites (p (w> 1)) in the amino acid sequence of RHAMM. The relative position
of known protein domains is shown. (B) Plot showing the position of potentially selected sites (p (w> 1)) in
the amino acid sequence of BRCA1. The relative position of known protein domains is shown.
doi:10.1371/journal.pone.0120020.g002
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be required to assess associations in these settings and their consistency with previous observa-
tions in the Ashkenazi Jewish population [1].
AURKA/CSTF1 association with breast cancer risk in BRCA2mutation
carriers
As theHMMR and AURKA-TPX2-TUBG1 gene products are functionally related in the regula-
tion of mammary epithelial polarization [4], the associations between variants at these loci that
were included on the iCOGS array and cancer risk in BRCA1/2mutation carriers were assessed
(S1 Table). No associations were observed for TPX2 and TUBG1, but there was an indication
of an association for a variant relatively close to AURKA; rs2426618 and breast cancer risk in
BRCA2mutation carriers, per-allele HR = 1.10, 95% CI 1.03–1.16, p = 0.005 (FDR-adjusted
p = 0.045; Fig. 3A). There was no evidence of association between this variant and breast can-
cer risk in BRCA1mutation carriers or between the same variant and ovarian cancer risk in
Fig 3. The AURKA/CSTF1 locus and breast cancer risk in BRCA2mutation carriers. (A) Forest plots
showing rs2426618 HRs and 95%CIs (retrospective likelihood trend estimation) for participating countries
(relatively small sample sets are not shown) ordered by sample size. Left and right panels show results for
BRCA1 and BRCA2mutation carriers, respectively. The sizes of the rectangles are proportional to the
corresponding study precision. (B) The rs2426618-containing region, including the genes, variation and
regulatory evidence in HMECs. Exons are marked by black-filled rectangles and the direction of transcription
is marked by arrows in the genomic structure. The chromosome 20 positions (bp) and linkage disequilibrium
structure from Caucasian HapMap individuals are also shown.
doi:10.1371/journal.pone.0120020.g003
HMMR Functional Module and Breast Cancer Risk
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either BRCA1 or BRCA2mutation carriers (p> 0.30). Consistent with the main analysis, the
competing risk model showed an rs2426618 association with breast cancer risk only in BRCA2
mutation carriers (p = 0.002).
The rs2426618 variant is located in intron 5 of a neighboring (distal) gene, CSTF1 (Fig. 3B).
Analogous to theHMMR setting, rs2426618 is relatively close (*30 kb) to the promoter region
of AURKA/CSTF1, which is active in mammary epithelial cells and differentially ERα-regulated
in poor-prognosis breast tumors (Fig. 3B). Association analysis with imputed SNPs within
*50 kb centered on rs2426618 (fully including AURKA and CSTF1) did not reveal stronger
evidence than that of rs2426618: a variant located in AURKA intron 8 (rs187966577, Fig. 3B)
was found to be similarly associated (p = 0.002). However, this variant was rare (MAF = 0.009)
and poorly imputed (r2 = 0.37). Finally, the analysis of rs2426618 by ERα tumor status in
BRCA2mutation carriers did not reveal specific associations: ERα-positive, per-allele
HR = 1.10, 95% CI 1.02–1.17, p = 0.010; ERα-negative, per-allele HR = 1.11,95% CI 0.97–1.26,
p = 0.15, pdifference = 0.89.
Potential genetic interactions in the AURKA-HMMR-TPX2-TUBG1
module
Given the above associations atHMMR and AURKA/CSTF1, the influence of GxG on breast
cancer risk in BRCA1/2mutation carriers was assessed between rs299290 and the genotyped
variants in AURKA/TPX2/TUBG1 (n = 22), and between rs2426618 and the genotyped variants
in TPX2/TUBG1 (n = 7). No GxG was detected for rs2426618-TPX2/TUBG1, but potential in-
teractions (unadjusted pinteraction values< 0.05) between rs299290 and AURKA/CSTF1 or
TUBG1 variants were suggested (Table 1). An interaction between rs299290 and rs6064391 (in
intron 2 of CSTF1, Fig. 3B) could reduce breast cancer risk in both BRCA1 and BRCA2muta-
tion carriers (interaction HRs = 0.87 and 0.73, respectively; Table 1). In the main effect analy-
sis, rs6064391 showed a suggestion of association with reduced breast cancer risk in BRCA2
mutation carriers: HR = 0.87, unadjusted p = 0.036. Conversely, an interaction between
rs299290 and rs11649877 (3’ region of TUBG1) could increase breast cancer risk in both
Table 1. Potential GxG associated with breast cancer risk in BRCA1/2 mutation carriers.
Genotype(s) (gene locus) HR* pinteraction
BRCA1 mutation carriers
rs299290-A/G (HMMR) 1.16
rs6064391-A/A (CSTF1) 1.09
rs299290-A/G—rs6064391-A/A 0.87 0.047
rs299290-A/G (HMMR) 1.07
rs11649877-A/G (TUBG1) 0.94
rs299290-A/G—rs11649877-A/G 1.33 0.014
BRCA2 mutation carriers
rs299290-G/G (HMMR) 1.32
rs6064391-A/C (CSTF1) 0.97
rs299290-A/G—rs6064391-A/C 0.73 0.034
rs299290-A/G (HMMR) 0.95
rs11649877-A/A (TUBG1) 0.87
rs299290-A/G—rs11649877-A/A 1.21 0.041
*Each estimate is derived from the interaction term of a Cox regression model.
doi:10.1371/journal.pone.0120020.t001
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BRCA1 and BRCA2mutation carriers (HRs = 1.33 and 1.21, respectively; Table 1). In the main
effect analysis, there was no evidence of rs11649877 association with breast cancer risk in
BRCA1 or BRCA2mutation carriers (p = 0.49). Genetic interactions frequently represent com-
plex molecular relationships and, thus, can be explained by multiple models of phenotypic dif-
ferences across genetic backgrounds [41], including those identified here. However, additional
studies are required to corroborate the findings.
Integrative studies in model organisms have shown that experimentally identified GxG
overlap with other types of gene and/or protein interactions (e.g., gene co-expression) to a de-
gree that is significantly higher than expected by chance [8]. Thus, we assessed the GxGs sug-
gested above for their equivalence with interactions between gene expression profiles across
breast tumors, considering breast cancer survival as the outcome. There are no large tumor se-
ries from BRCA1/2mutation carriers that allow gene expression interactions in these mutation
backgrounds to be assessed; therefore our analysis was restricted to sporadic cases and aimed
to explore complex relationships between HMMR and AURKA or TUBG1. Using the NKI-295
dataset [22],HMMR expression was found to be significantly associated with overall survival:
two microarray probes gave identical results: HR = 1.78 and p = 0.001. AURKA expression was
also found to be associated with overall survival (single probe HR = 2.07, p = 3.3 x 10−9) but,
notably, the combined model with HMMR indicated a protective interaction: the HRs for both
HMMR and AURKA probe combinations were 0.57 and 0.55, pinteraction values = 0.026, respec-
tively (Fig. 4A). The combined HMMR and TUBG1 expressions also suggested an interaction,
but in this case “aggravating”: the HRs for bothHMMR probe combinations with a TUBG1
probe were 1.84 and 2.16, pinteraction = 0.041 and 0.009, respectively (Fig. 4B). The expression
of TUBG1 alone was not found to be associated with overall survival (p = 0.12). Together, these
results could indicate a functional correspondence for interactions influencing both breast can-
cer development and progression. However, the precise effects of the corresponding risk alleles
remain to be elucidated.
Discussion
The results of this study expand on the previous suggestion that variation in HMMR is specifi-
cally associated with breast cancer risk in BRCA1mutation carriers [4]. By analyzing a much
larger number of carriers—genotyped using the high-quality iCOGS approach [11,12]—we
Fig 4. Gene expression interactions in breast cancer survival. (A) Kaplan–Meier survival curves based
on categorization ofHMMR (probe NM_012484) and AURKA (NM_003600) expression in tertiles (low,
medium or high expression). For simplicity, only the tertiles for “high” AURKA are shown. The tumours with
high expression levels for both genes were not those with the poorest prognosis. (B) Kaplan–Meier survival
curves based on categorization of HMMR (NM_012484) and TUBG1 (NM_016437) expression in tertiles
(low, medium or high expression). For simplicity, only the tertiles for “high” HMMR are shown. The cases with
high expression levels for both genes were those with the poorest prognosis.
doi:10.1371/journal.pone.0120020.g004
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were able to confirm the association of this locus, and to demonstrate that the strongest signal
corresponded to rs299290. No specific effect was revealed when analyzing this association by
ERα tumor status. Larger carrier series may be required to comprehensively evaluate associa-
tions by tumor subtype or, conversely, to establish that variation inHMMR interacts with
Class I BRCA1mutations to give rise to any type of tumor. In this context, mapping of the pro-
tein and/or functional domains interacting between BRCA1 and RHAMMwould be necessary
to decipher the role of rs299290, if any, and of the observed potential positive selection. With
regard to the results obtained for BRCA2mutation carriers, the opposite direction of the poten-
tial association with ERα-negative breast cancer compared with the association observed for
BRCA1mutation carriers is intriguing. Opposite effects between cancer subtypes have been ob-
served for other modifier loci [16] and, thus, potentially inform on opposing functional roles in
biological processes influencing carcinogenesis. In other words, alteration of RHAMM func-
tion in mammary epithelial differentiation may have a differential effect on breast cancer risk
depending on whether it occurs in a BRCA1- or BRCA2-mutated background.
The study of gene loci functionally related to HMMR suggests an association between varia-
tion in AURKA/CSTF1 and risk of breast cancer among BRCA2mutation carriers. While there
were initial conflicting results for AURKA associations with breast cancer risk [5,42], it is inter-
esting to note that a population case-control study [43] identified variants in the AURKA pro-
moter region associated with breast cancer risk in the same direction as detected in our
analysis. The minor allele of rs6064389 was shown to be protective in the general population
[43], and a similar association was observed in the analysis of BRCA2mutation carriers:
HR = 0.93, p = 0.021; not significant in BRCA1mutation carriers, p = 0.25. This variant is par-
tially correlated with rs2426618 (r2 = 0.63), and more strongly correlated with rs6064391 (r2 =
0.86), which might interact with rs299290.
In addition to the main effects, interaction between HMMR and AURKA, and between
HMMR and TUBG1 could influence breast cancer risk in BRCA1 and BRCA2mutation carri-
ers. The interactions did not remain statistically significant after corrections for multiple test-
ing and, therefore, additional studies are warranted to investigate these findings further.
Combined expression of HMMR and AURKA, and HMMR and TUBG1 in sporadic breast tu-
mors appeared to influence patients’ survival differentially. These results could be analogous to
those observed for breast cancer risk, but it remains unknown how the corresponding risk al-
leles may alter gene expression and/or protein function. In this context, over-expression of
HMMR, AURKA or TUBG1 impairs mammary epithelial polarization [4] and the rs299290
risk allele could be associated with relatively higher levels ofHMMR expression [1,4], which
would be consistent with the observed interactions. However, other studies on the potential
regulatory impact of this variant and/or the link to selective constraints are needed. It is also
important to note that the altered gene products may not be those included in the depicted
functional module, but rather other products from the corresponding chromosomal regions.
In summary, centered on the AURKA-HMMR-TPX2-TUBG1 functional module that regu-
lates mammary epithelial polarization, this study confirms previous association results for
HMMR rs299290 and suggests novel associations (for AURKA/CSTF1 and HMMR-rs299290
interactions) with breast cancer risk in BRCA1 and/or BRCA2mutation carriers.
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